Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Bausch + Lomb Corporation ( (BLCO) ) is now available.
Bausch + Lomb Corporation announced the allocation of $2.8 billion in new term B loans to refinance its existing term B loans due 2031 and 2028. This refinancing effort is expected to reduce the applicable margin rates and extend the maturity of some loans, potentially enhancing the company’s financial flexibility and operational stability. The transactions are anticipated to close in the first quarter of 2026, although there is no guarantee of completion on the proposed terms.
The most recent analyst rating on (BLCO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
Bausch + Lomb’s overall stock score is driven by strong technical indicators and positive strategic outlook from recent corporate events. However, financial performance and valuation concerns, particularly negative profitability and cash flow issues, weigh down the score.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb Corporation is a leading global eye health company dedicated to improving vision and quality of life. The company offers a wide range of products including contact lenses, prescription products, over-the-counter options, and surgical devices, focusing on innovation and improving eye health standards.
Average Trading Volume: 494,880
Technical Sentiment Signal: Buy
Current Market Cap: $5.93B
Find detailed analytics on BLCO stock on TipRanks’ Stock Analysis page.